Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005

Psychiatric Services

Volumn 61, Issue 2, 2010, Pages 123-129

  Pathak, Prathamesh ^a,b   West, Donna ^a,c   Martin, Bradley C ^a   Helm, Mark E ^a   Henderson, Crystal ^a,d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b IQVIA   (United States)

^c University of Mississippi   (United States)

^d Medco Health Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADJUSTMENT DISORDER; ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; CHILD; CONDUCT DISORDER; DATA BASE; DEMOGRAPHY; DEPRESSION; DEVELOPMENTAL DISORDER; DRUG DEPENDENCE; DRUG INDICATION; DRUG USE; EATING DISORDER; EPILEPSY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAID; MENTAL DISEASE; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PSYCHOSIS; TIC;

EID: 76049084742     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2010.61.2.123     Document Type: Article

References (22)

1. Cooper WO, Hickson GB, Fuchs C, et al: New users of antipsychotic medications among children enrolled in TennCare. Archives of Pediatric and Adolescent Medicine 158:753-759, 2004
2. Martin A, Leslie D: Trends in psychotropic medication costs for children and adolescents, 1997-2000. Archives of Pediatric and Adolescent Medicine 157:997-1004, 2003
3. Pappadopulos E, Jensen PS, Schur SB, et al: "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophrenia Bulletin 28:111-121, 2002
4. Patel NC, Crismon ML, Hoagwood K, et al: Trends in the use of typical and atypical antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 44:548-556, 2005
5. Zito JM, Safer DJ, DosReis S, et al: Psychotropic practice patterns for youth: a 10-year perspective. Archives of Pediatric and Adolescent Medicine 157:17-25, 2003
6. Campbell M, Rapoport JL, Simpson GM: Antipsychotics in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 38:537-545, 1999
7. Curtis LH, Masselink LE, Ostbye T, et al: Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Archives of Pediatric and Adolescent Medicine 159:362-366, 2005
8. Cooper WO, Arbogast PG, Ding H, et al: Trends in prescribing of antipsychotic medications for US children. Ambulatory Pediatrics 6:79-83, 2006
9. Olfson M, Blanco C, Liu L, et al: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 63:679-685, 2006
10. Cortese L, Pourcher-Bouchard E, Williams R: Assessment and management of antipsychotic-induced adverse events. Canadian Journal of Psychiatry 43(suppl 1):15S-20S, 1998
11. Essock SM, Hargreaves WA, Dohm FA, et al: Clozapine eligibility among state hospital patients. Schizophrenia Bulletin 22:15-25, 1996
12. Kelly DL, Love RC: Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Psychopharmacology Bulletin 35:66-79, 2001
13. Leucht S, Pitschel-Walz G, Abraham D, et al: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophrenia Research 35:51-68, 1999
14. Data on file, study 31-03-240. Rockville, Md, Otsuka Maryland Research Institute, 2005-2007
15. Chen H, Deshpande AD, Jiang R, et al: An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. Pharmacoepidemiology Drug Safety 14:629-638, 2005
16. Harpaz-Rotem I, Leslie DL, Martin A, et al: Changes in child and adolescent inpatient psychiatric admission diagnoses between 1995 and 2000. Social Psychiatry and Psychiatric Epidemiology 40:642-647, 2005
17. Levine LJ, Schwarz DF, Argon J, et al: Discharge disposition of adolescents admitted to medical hospitals after attempting suicide. Archives of Pediatric and Adolescent Medicine 159:860-866, 2005
18. Harpaz-Rotem I, Leslie D, Rosenheck RA: Treatment retention among children entering a new episode of mental health care. Psychiatric Services 55:1022-1028, 2004
19. Guevara J, Lozano P, Wickizer T, et al: Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 108:71-78, 2001
20. Guevara J, Lozano P, Wickizer T, et al: Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics 109:733-739, 2002
21. Blumer JL: Off-label uses of drugs in children. Pediatrics 104:598-602, 1999
22. Harris RP, Helfand M, Woolf SH, et al: Current methods of the US Preventive Services Task Force: a review of the process. American Journal of Preventive Medicine 20:21-35, 2001